China Universal Asset Management Company’s Fate Therapeutics FATE Stock Holding History

China Universal Asset Management Company’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,216	Closed	-$25.5K	–	512
2025 Q3	$25.5K	Sell	20,216 -2,808	-12%	-$3.03K	﹤0.01%	456
2025 Q2	$25.8K	Buy	23,024 +179	+0.8%	+$208	﹤0.01%	446
2025 Q1	$18.1K	Sell	22,845 -1,305	-5%	-$1.6K	﹤0.01%	459
2024 Q4	$39.8K	Buy	+24,150	New	+$60.9K	﹤0.01%	459
2023 Q4	–	Sell	-2,526	Closed	-$5.36K	–	446
2023 Q3	$5.36K	Buy	2,526 +1,236	+96%	+$4.09K	﹤0.01%	385
2023 Q2	$6.14K	Sell	1,290 -40	-3%	-$221	﹤0.01%	353
2023 Q1	$7.58K	Buy	1,330 +343	+35%	+$2.07K	﹤0.01%	327
2022 Q4	$9.96K	Buy	987 +78	+9%	+$1.47K	﹤0.01%	227
2022 Q3	$20K	Buy	+909	New	+$26.3K	0.01%	156

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

China Universal Asset Management Company's FATE Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 20,216 shares — an estimated $25.5K sold.

China Universal Asset Management Company first reported a position in FATE in Q3 2022 and held it in 9 quarters. The position peaked at $39.8K in Q4 2024. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

China Universal Asset Management Company reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
China Universal Asset Management Company sold 20,216 Fate Therapeutics shares in Q4 2025, an estimated $25.5K.
China Universal Asset Management Company first reported a position in Fate Therapeutics in Q3 2022 and held it in 9 quarters.
China Universal Asset Management Company's Fate Therapeutics position peaked at $39.8K in Q4 2024.
146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.